Compare GEO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | NAMS |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1996 | N/A |
| Metric | GEO | NAMS |
|---|---|---|
| Price | $30.88 | $29.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $39.67 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.8M | 961.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $2,263,420,000.00 | N/A |
| Revenue This Year | $13.74 | $17.96 |
| Revenue Next Year | $9.99 | $540.65 |
| P/E Ratio | $107.52 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $21.14 |
| 52 Week High | $32.25 | $42.21 |
| Indicator | GEO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 41.00 |
| Support Level | $28.74 | $29.23 |
| Resistance Level | $32.25 | $37.29 |
| Average True Range (ATR) | 0.98 | 1.88 |
| MACD | -0.10 | -0.42 |
| Stochastic Oscillator | 64.11 | 8.00 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.